MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
LIVN stock logo

LIVN

LivaNova PLC

$63.79
-0.84
 (-1.3%)
[ms_data_label text=’Delayed data’]
Exchange:  NASDAQ
Market Cap:  3.489B
Shares Outstanding:  7.846M
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Medical – Devices
   
CEO:  Vladimir A. Makatsaria
Full Time Employees:  2900
Address: 
20 Eastbourne Terrace
London
W2 6LG
GB
Website:  https://www.livanova.com
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products, such as cardiopulmonary and respiratory support solutions. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.

Click to read more…

Revenue Segmentation

MARKETSnap
MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2025/05/11 — Q1 quarter 2025

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue1,153,5451,253,4371,388,100
Gross Profit771,250870,873939,900
EBITDA38,483202,524-129,500
Operating Income-68,498129,051199,400
Net Income17,54663,234-242,500

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets2,429,5632,506,3892,606,100
Total Liabilities1,151,9351,186,1311,406,100
Total Stockholders Equity1,277,6281,320,2581,200,000
Total Debt640,404676,773425,000
Cash and Cash Equivalents266,504428,858635,600

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow74,914183,038254,300
Capital Expenditure-34,981-47,107-81,100
Free Cash Flow39,933135,931173,200
Net Income17,54663,234-242,500
Net Change in Cash62,254145,684-88,000

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)1,800,256.942Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)1,887,425.686Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)1,860,000Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)45,283.813Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)47,476.463Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)46,786.595Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)334,757.536Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)356,041.421Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)349,345.006Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)784,694.248Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)822,689.276Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)810,734.994Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)6.410Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)6.530Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)6.140Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)3Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)1Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
1.253B  ?P/S
 (TTM)
: 
2.4
?Net Income
 (TTM)
: 
63.234M  ?P/E
 (TTM)
: 
-13.71
?Enterprise Value
 (TTM)
: 
3.174B  ?EV/FCF
 (TTM)
: 
18.31
?Dividend Yield
 (TTM)
: 
0  ?Payout Ratio
 (TTM)
: 
0
?ROE
 (TTM)
: 
-0.21  ?ROIC
 (TTM)
: 
0.11
?Net Debt
 (TTM)
: 
-46783000  ?Debt/Equity
 (TTM)
: 
0.39
?P/B
 (TTM)
: 
2.77  ?Current Ratio
 (TTM)
: 
1.36

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
15.15Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MARKETSnap estimates LIVN intrinsic value between $36.65 – $36.94 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate LIVN Intrinsic Value

Common questions about LIVN valuation

Is LivaNova PLC (LIVN) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for LivaNova PLC (LIVN) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is LIVN a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether LIVN trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is LIVN’s P/E ratio?

You can see LIVN’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for LIVN?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is LIVN a good long-term investment?

Whether LIVN fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

LIVN

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

[ms_data_label text="Daily snapshot"]

-1.3
MARKETSnap

Trading Metrics:

[ms_session_rows_unavailable]
Open: [ms_cell_or_dash table='trading_quote' column='open']   Previous Close: [ms_cell_or_dash table='trading_quote' column='previousClose']
Day Low: [ms_cell_or_dash table='trading_quote' column='dayLow']   Day High: [ms_cell_or_dash table='trading_quote' column='dayHigh']
Year Low: 32.48   Year High: 71.92
Price Avg 50: 64.89   Price Avg 200: 56.75
Volume: 666827   Average Volume: 840506

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Annals of Internal Medicine Publishes 12-Month Results from LivaNova's OSPREY Clinical Study for Obstructive Sleep Apnea
20-04-2026 17:05
Annals of Internal Medicine Publishes 12-Month Results from LivaNova's OSPREY Clinical Study for Obstructive Sleep Apnea
LivaNova Expands OSA Care With FDA-Approved aura6000 System
25-03-2026 12:22
LivaNova Expands OSA Care With FDA-Approved aura6000 System
LivaNova to Announce First-Quarter 2026 Results
25-03-2026 09:00
LivaNova to Announce First-Quarter 2026 Results
LivaNova PLC (NASDAQ:LIVN) Receives Consensus Rating of “Moderate Buy” from Brokerages
23-03-2026 02:40
LivaNova PLC (NASDAQ:LIVN) Receives Consensus Rating of “Moderate Buy” from Brokerages
All You Need to Know About LivaNova (LIVN) Rating Upgrade to Buy
05-03-2026 13:00
All You Need to Know About LivaNova (LIVN) Rating Upgrade to Buy
LivaNova PLC (LIVN) Q4 2025 Earnings Call Transcript
25-02-2026 17:27
LivaNova PLC (LIVN) Q4 2025 Earnings Call Transcript

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States
  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read